Ventyx Biosciences has shared phase 2a data on a Parkinson’s disease prospect that has caught the eye of Sanofi. The readout shows the effect of VTX3232 on biomarkers, providing some of the data that ...

Ventyx Biosciences disclosed positive top-line results from its Phase 2a study of VTX3232 in patients with early-stage Parkinson's disease.

Investing.com -- Ventyx Biosciences (NASDAQ: VTYX) stock was unchanged following the announcement of top-line data from its Phase 2a safety and biomarker trial evaluating VTX3232 in patients with ...

Scientists from the University of Rochester and other institutions have uncovered new evidence that exposure to ...

They were designed to treat diabetes, then prescribed for weight loss, and now—as researchers are finding—they might hold the ...

Psilocybin therapy improved cognitive performance, reduced mood dysfunction, motor, and nonmotor symptoms in patients with Parkinson disease.

A large longitudinal study found that pesticide exposure and caffeinated soda intake were linked to more severe motor ...

Scientists have found new evidence that bacteria in the mouth and gut could be linked to memory problems in people with ...

The Swiss drugmaker said it was “encouraged” by the signs of effectiveness of the drug, developed by biotech Prothena, showed ...

Roche's Venclexta failure does not affect the oncology pipeline, as HER2 franchise continues to drive revenue growth. Click ...

The Freudenthal Center for Parkinson's Disease will host the "Unite and Fight" Gala on Aug. 12, 2025, at the Stoney Creek Hotel. Doors will open at 5 p.m., where guests can mingle and enjoy a cash bar ...

For decades, researchers have wondered why some people with risky gene variants go on to develop Parkinson’s disease, while ...